Expression of MUC1 recognized by a monoclonal antibody MY.1E12 is a useful biomarker for tumor aggressiveness of carcinoma of the ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2004-07

AUTHORS

Toru Kawamoto, Junichi Shoda, Naoki Miyahara, Hideo Suzuki, Masato Furukawa, Takeshi Todoroki, Naomi Tanaka, Tatsuro Irimura

ABSTRACT

The overall outcome of gallbladder carcinoma has not been favorable because of frequent recurrence at distant sites after surgery. A high-level expression of MUC1 recognized by a monoclonal antibody (mAb), MY.1E12, is correlated with poor survival in several types of carcinomas. There is a need to find new prognostic parameters that can give further insights into tumor aggressiveness of the disease. Immunohistochemistry was performed to determine the expression level of mAb MY.1E12-reactive-MUC1 (MY.1E12-MUC1) in 79 cases of gallbladder carcinoma of different depths of invasion and to determine the correlation of the expression level with clinicopathological findings. The cellular distribution of MY.1E12-MUC1 was heterogeneous among carcinomas of different depths of invasion. Immunohistochemical localization was classified into apical, cytoplasmic and stromal types based on the predominant cellular distribution. In 35 cases of pT2 carcinoma in which curative resections had been performed, the localization was apical type in 54%, cytoplasmic type in 66%, and stromal type in 56% of the cases at the deepest invading sites in the subserosal layer. Postsurgical recurrences at distant sites were seen in 11 of 18 cases of pT2 carcinoma (61%) that had more than or equal to 10% of the cancerous epithelia showing stromal localization of MY.1E12-MUC1 at the deepest invading sites (stromal group) and in 3 of 17 cases (18%) that had less than 10% of the cancerous epithelia showing stromal localization (nonstromal group). The postsurgical 5-year survival rate was significantly poorer in the former (54%) than in the latter (79%; P = 0.049). In 38 cases of pT3 and pT4 carcinomas, the frequency of synchronous distant organ metastasis at the time of diagnosis was significantly higher in cases in the stromal group (61%) than in cases in the nonstromal group (20%). Moreover, in 73 cases of pT2, pT3 and pT4 carcinomas, the expression rate of abnormal localization of E-cadherin was significantly higher in the stromal group (63%) than in the nonstromal group (30%). The MUC1 mRNA levels revealed by in situ hybridization would not be a determinant important for the stromal localization. The stromal localization of MY.1E12-MUC1 may be a phenotype serving as a unique biological feature associated with the tumor aggressiveness of gallbladder carcinoma, such as the tendency to form distant organ metastasis.Abbreviations:ISH–in situ hybridization; mAb – monoclonal antibody; mRNA – messenger ribonucleic acid; MUC – mucin core polypeptide; p – pathological; TNM – tumor node metastasis More... »

PAGES

353-362

Identifiers

URI

http://scigraph.springernature.com/pub.10.1023/b:clin.0000046177.70405.cb

DOI

http://dx.doi.org/10.1023/b:clin.0000046177.70405.cb

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1024529919

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/15554392


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biomarkers, Tumor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cadherins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Gallbladder Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunohistochemistry", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mucin-1", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Invasiveness", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "RNA, Messenger", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Gastrointestinal Surgery, Institute of Clinical Medicine, The University of Tsukuba, Tsukubashi, Ibaraki, Japan", 
          "id": "http://www.grid.ac/institutes/grid.20515.33", 
          "name": [
            "Department of Gastrointestinal Surgery, Institute of Clinical Medicine, The University of Tsukuba, Tsukubashi, Ibaraki, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kawamoto", 
        "givenName": "Toru", 
        "id": "sg:person.016654252332.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016654252332.36"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Gastroenterology, Institute of Clinical Medicine, The University of Tsukuba, Tsukubashi, Ibaraki, Japan", 
          "id": "http://www.grid.ac/institutes/grid.20515.33", 
          "name": [
            "Department of Gastroenterology, Institute of Clinical Medicine, The University of Tsukuba, Tsukubashi, Ibaraki, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shoda", 
        "givenName": "Junichi", 
        "id": "sg:person.01167712513.14", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01167712513.14"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cancer Biology and Molecular Immunology, Faculty of Pharmaceutical Sciences, The University of Tokyo, Bunkyoku, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.26999.3d", 
          "name": [
            "Department of Gastroenterology, Institute of Clinical Medicine, The University of Tsukuba, Tsukubashi, Ibaraki, Japan", 
            "Department of Cancer Biology and Molecular Immunology, Faculty of Pharmaceutical Sciences, The University of Tokyo, Bunkyoku, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Miyahara", 
        "givenName": "Naoki", 
        "id": "sg:person.01342335052.95", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01342335052.95"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Gastroenterology, Institute of Clinical Medicine, The University of Tsukuba, Tsukubashi, Ibaraki, Japan", 
          "id": "http://www.grid.ac/institutes/grid.20515.33", 
          "name": [
            "Department of Gastroenterology, Institute of Clinical Medicine, The University of Tsukuba, Tsukubashi, Ibaraki, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Suzuki", 
        "givenName": "Hideo", 
        "id": "sg:person.014234426664.03", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014234426664.03"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "2nd Department of Surgery, Nagasaki Central National Hospital, Ohmura-shi, Nagasaki, Japan", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "2nd Department of Surgery, Nagasaki Central National Hospital, Ohmura-shi, Nagasaki, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Furukawa", 
        "givenName": "Masato", 
        "id": "sg:person.0733157352.71", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0733157352.71"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Gastrointestinal Surgery, Institute of Clinical Medicine, The University of Tsukuba, Tsukubashi, Ibaraki, Japan", 
          "id": "http://www.grid.ac/institutes/grid.20515.33", 
          "name": [
            "Department of Gastrointestinal Surgery, Institute of Clinical Medicine, The University of Tsukuba, Tsukubashi, Ibaraki, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Todoroki", 
        "givenName": "Takeshi", 
        "id": "sg:person.011557753737.86", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011557753737.86"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Gastroenterology, Institute of Clinical Medicine, The University of Tsukuba, Tsukubashi, Ibaraki, Japan", 
          "id": "http://www.grid.ac/institutes/grid.20515.33", 
          "name": [
            "Department of Gastroenterology, Institute of Clinical Medicine, The University of Tsukuba, Tsukubashi, Ibaraki, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tanaka", 
        "givenName": "Naomi", 
        "id": "sg:person.014306602014.93", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014306602014.93"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cancer Biology and Molecular Immunology, Faculty of Pharmaceutical Sciences, The University of Tokyo, Bunkyoku, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.26999.3d", 
          "name": [
            "Department of Cancer Biology and Molecular Immunology, Faculty of Pharmaceutical Sciences, The University of Tokyo, Bunkyoku, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Irimura", 
        "givenName": "Tatsuro", 
        "id": "sg:person.01356327470.60", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01356327470.60"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/sj.bjc.6690355", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047938576", 
          "https://doi.org/10.1038/sj.bjc.6690355"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf01658724", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023802947", 
          "https://doi.org/10.1007/bf01658724"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2004-07", 
    "datePublishedReg": "2004-07-01", 
    "description": "The overall outcome of gallbladder carcinoma has not been favorable because of frequent recurrence at distant sites after surgery. A high-level expression of MUC1 recognized by a monoclonal antibody (mAb), MY.1E12, is correlated with poor survival in several types of carcinomas. There is a need to find new prognostic parameters that can give further insights into tumor aggressiveness of the disease. Immunohistochemistry was performed to determine the expression level of mAb MY.1E12-reactive-MUC1 (MY.1E12-MUC1) in 79 cases of gallbladder carcinoma of different depths of invasion and to determine the correlation of the expression level with clinicopathological findings. The cellular distribution of MY.1E12-MUC1 was heterogeneous among carcinomas of different depths of invasion. Immunohistochemical localization was classified into apical, cytoplasmic and stromal types based on the predominant cellular distribution. In 35 cases of pT2 carcinoma in which curative resections had been performed, the localization was apical type in 54%, cytoplasmic type in 66%, and stromal type in 56% of the cases at the deepest invading sites in the subserosal layer. Postsurgical recurrences at distant sites were seen in 11 of 18 cases of pT2 carcinoma (61%) that had more than or equal to 10% of the cancerous epithelia showing stromal localization of MY.1E12-MUC1 at the deepest invading sites (stromal group) and in 3 of 17 cases (18%) that had less than 10% of the cancerous epithelia showing stromal localization (nonstromal group). The postsurgical 5-year survival rate was significantly poorer in the former (54%) than in the latter (79%; P = 0.049). In 38 cases of pT3 and pT4 carcinomas, the frequency of synchronous distant organ metastasis at the time of diagnosis was significantly higher in cases in the stromal group (61%) than in cases in the nonstromal group (20%). Moreover, in 73 cases of pT2, pT3 and pT4 carcinomas, the expression rate of abnormal localization of E-cadherin was significantly higher in the stromal group (63%) than in the nonstromal group (30%). The MUC1 mRNA levels revealed by in situ hybridization would not be a determinant important for the stromal localization. The stromal localization of MY.1E12-MUC1 may be a phenotype serving as a unique biological feature associated with the tumor aggressiveness of gallbladder carcinoma, such as the tendency to form distant organ metastasis.Abbreviations:ISH\u2013in situ hybridization; mAb \u2013 monoclonal antibody; mRNA \u2013 messenger ribonucleic acid; MUC \u2013 mucin core polypeptide; p \u2013 pathological; TNM \u2013 tumor node metastasis", 
    "genre": "article", 
    "id": "sg:pub.10.1023/b:clin.0000046177.70405.cb", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094856", 
        "issn": [
          "0262-0898", 
          "1573-7276"
        ], 
        "name": "Clinical & Experimental Metastasis", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "21"
      }
    ], 
    "keywords": [
      "distant organ metastasis", 
      "gallbladder carcinoma", 
      "stromal localization", 
      "tumor aggressiveness", 
      "pT2 carcinomas", 
      "organ metastasis", 
      "stromal group", 
      "stromal type", 
      "pT4 carcinomas", 
      "cancerous epithelium", 
      "time of diagnosis", 
      "new prognostic parameters", 
      "types of carcinoma", 
      "distant sites", 
      "expression levels", 
      "monoclonal antibody MY", 
      "cellular distribution", 
      "MUC1 mRNA levels", 
      "curative resection", 
      "subserosal layer", 
      "situ hybridization", 
      "clinicopathological findings", 
      "postsurgical recurrence", 
      "prognostic parameters", 
      "poor survival", 
      "cases of pT2", 
      "frequent recurrence", 
      "useful biomarker", 
      "carcinoma", 
      "Immunohistochemical localization", 
      "survival rate", 
      "overall outcome", 
      "monoclonal antibodies", 
      "expression rate", 
      "apical type", 
      "mRNA levels", 
      "abnormal localization", 
      "E-cadherin", 
      "MUC1", 
      "recurrence", 
      "metastasis", 
      "pT3", 
      "cases of pT3", 
      "epithelium", 
      "unique biological features", 
      "antibodies", 
      "aggressiveness", 
      "biological features", 
      "group", 
      "invasion", 
      "ribonucleic acid", 
      "high-level expression", 
      "resection", 
      "surgery", 
      "gallbladder", 
      "cases", 
      "expression", 
      "immunohistochemistry", 
      "levels", 
      "disease", 
      "diagnosis", 
      "biomarkers", 
      "survival", 
      "outcomes", 
      "localization", 
      "ISH", 
      "cytoplasmic type", 
      "core polypeptides", 
      "further insight", 
      "rate", 
      "pT2", 
      "phenotype", 
      "sites", 
      "findings", 
      "hybridization", 
      "types", 
      "correlation", 
      "acid", 
      "need", 
      "polypeptide", 
      "frequency", 
      "time", 
      "tendency", 
      "features", 
      "MY", 
      "insights", 
      "distribution", 
      "parameters", 
      "depth", 
      "different depths", 
      "layer"
    ], 
    "name": "Expression of MUC1 recognized by a monoclonal antibody MY.1E12 is a useful biomarker for tumor aggressiveness of carcinoma of the gallbladder", 
    "pagination": "353-362", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1024529919"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1023/b:clin.0000046177.70405.cb"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "15554392"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1023/b:clin.0000046177.70405.cb", 
      "https://app.dimensions.ai/details/publication/pub.1024529919"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-09-02T15:50", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_393.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1023/b:clin.0000046177.70405.cb"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1023/b:clin.0000046177.70405.cb'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1023/b:clin.0000046177.70405.cb'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1023/b:clin.0000046177.70405.cb'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1023/b:clin.0000046177.70405.cb'


 

This table displays all metadata directly associated to this object as RDF triples.

262 TRIPLES      21 PREDICATES      130 URIs      120 LITERALS      18 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1023/b:clin.0000046177.70405.cb schema:about N16d440ae80604dd7a6702333b7f41b5f
2 N175e6c6ca67a48c09db4f950be480190
3 N430936ba4fa64dd1966532cde29effea
4 N56fb9ec579bc4ceaae6b9655e9af580e
5 N5875b1553d404c7482580299be260bbd
6 N5ca4b867ef864746b7d2eb050921b4f7
7 N5d3bb014ffee4180825c7bdd6eec36e3
8 N5dba2529a71141c78849b878c4c8bd67
9 Naa6bffdbbbcb4026bee0ac29e8dabf85
10 Nddf2ce8a67934a7da578eba0010b3851
11 Nf40467e1394c4f39b7b3ce61ae70095b
12 anzsrc-for:11
13 anzsrc-for:1112
14 schema:author N4f650c72bc01482aac98c81800f7d69f
15 schema:citation sg:pub.10.1007/bf01658724
16 sg:pub.10.1038/sj.bjc.6690355
17 schema:datePublished 2004-07
18 schema:datePublishedReg 2004-07-01
19 schema:description The overall outcome of gallbladder carcinoma has not been favorable because of frequent recurrence at distant sites after surgery. A high-level expression of MUC1 recognized by a monoclonal antibody (mAb), MY.1E12, is correlated with poor survival in several types of carcinomas. There is a need to find new prognostic parameters that can give further insights into tumor aggressiveness of the disease. Immunohistochemistry was performed to determine the expression level of mAb MY.1E12-reactive-MUC1 (MY.1E12-MUC1) in 79 cases of gallbladder carcinoma of different depths of invasion and to determine the correlation of the expression level with clinicopathological findings. The cellular distribution of MY.1E12-MUC1 was heterogeneous among carcinomas of different depths of invasion. Immunohistochemical localization was classified into apical, cytoplasmic and stromal types based on the predominant cellular distribution. In 35 cases of pT2 carcinoma in which curative resections had been performed, the localization was apical type in 54%, cytoplasmic type in 66%, and stromal type in 56% of the cases at the deepest invading sites in the subserosal layer. Postsurgical recurrences at distant sites were seen in 11 of 18 cases of pT2 carcinoma (61%) that had more than or equal to 10% of the cancerous epithelia showing stromal localization of MY.1E12-MUC1 at the deepest invading sites (stromal group) and in 3 of 17 cases (18%) that had less than 10% of the cancerous epithelia showing stromal localization (nonstromal group). The postsurgical 5-year survival rate was significantly poorer in the former (54%) than in the latter (79%; P = 0.049). In 38 cases of pT3 and pT4 carcinomas, the frequency of synchronous distant organ metastasis at the time of diagnosis was significantly higher in cases in the stromal group (61%) than in cases in the nonstromal group (20%). Moreover, in 73 cases of pT2, pT3 and pT4 carcinomas, the expression rate of abnormal localization of E-cadherin was significantly higher in the stromal group (63%) than in the nonstromal group (30%). The MUC1 mRNA levels revealed by in situ hybridization would not be a determinant important for the stromal localization. The stromal localization of MY.1E12-MUC1 may be a phenotype serving as a unique biological feature associated with the tumor aggressiveness of gallbladder carcinoma, such as the tendency to form distant organ metastasis.Abbreviations:ISH–in situ hybridization; mAb – monoclonal antibody; mRNA – messenger ribonucleic acid; MUC – mucin core polypeptide; p – pathological; TNM – tumor node metastasis
20 schema:genre article
21 schema:isAccessibleForFree false
22 schema:isPartOf N48acac754e234b0299cb8745ffa33936
23 Nff74ee61541d490eb17f1128ac1c88fd
24 sg:journal.1094856
25 schema:keywords E-cadherin
26 ISH
27 Immunohistochemical localization
28 MUC1
29 MUC1 mRNA levels
30 MY
31 abnormal localization
32 acid
33 aggressiveness
34 antibodies
35 apical type
36 biological features
37 biomarkers
38 cancerous epithelium
39 carcinoma
40 cases
41 cases of pT2
42 cases of pT3
43 cellular distribution
44 clinicopathological findings
45 core polypeptides
46 correlation
47 curative resection
48 cytoplasmic type
49 depth
50 diagnosis
51 different depths
52 disease
53 distant organ metastasis
54 distant sites
55 distribution
56 epithelium
57 expression
58 expression levels
59 expression rate
60 features
61 findings
62 frequency
63 frequent recurrence
64 further insight
65 gallbladder
66 gallbladder carcinoma
67 group
68 high-level expression
69 hybridization
70 immunohistochemistry
71 insights
72 invasion
73 layer
74 levels
75 localization
76 mRNA levels
77 metastasis
78 monoclonal antibodies
79 monoclonal antibody MY
80 need
81 new prognostic parameters
82 organ metastasis
83 outcomes
84 overall outcome
85 pT2
86 pT2 carcinomas
87 pT3
88 pT4 carcinomas
89 parameters
90 phenotype
91 polypeptide
92 poor survival
93 postsurgical recurrence
94 prognostic parameters
95 rate
96 recurrence
97 resection
98 ribonucleic acid
99 sites
100 situ hybridization
101 stromal group
102 stromal localization
103 stromal type
104 subserosal layer
105 surgery
106 survival
107 survival rate
108 tendency
109 time
110 time of diagnosis
111 tumor aggressiveness
112 types
113 types of carcinoma
114 unique biological features
115 useful biomarker
116 schema:name Expression of MUC1 recognized by a monoclonal antibody MY.1E12 is a useful biomarker for tumor aggressiveness of carcinoma of the gallbladder
117 schema:pagination 353-362
118 schema:productId N6c66bd1a3eb14ec9ae3a5c410b65eeb8
119 N8f7b5503baa3453ca2ab7d89e63d3047
120 Nbebf6c78173340d99df54493a1c1679d
121 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024529919
122 https://doi.org/10.1023/b:clin.0000046177.70405.cb
123 schema:sdDatePublished 2022-09-02T15:50
124 schema:sdLicense https://scigraph.springernature.com/explorer/license/
125 schema:sdPublisher N2cce0b0e0f124a058aff8412959cefb5
126 schema:url https://doi.org/10.1023/b:clin.0000046177.70405.cb
127 sgo:license sg:explorer/license/
128 sgo:sdDataset articles
129 rdf:type schema:ScholarlyArticle
130 N075cc5d1d2c645008c3e09ba9096efc9 rdf:first sg:person.011557753737.86
131 rdf:rest N6d20e64f21f54c05a9675a37e6e4dfec
132 N16d440ae80604dd7a6702333b7f41b5f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Immunohistochemistry
134 rdf:type schema:DefinedTerm
135 N175e6c6ca67a48c09db4f950be480190 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Female
137 rdf:type schema:DefinedTerm
138 N2cce0b0e0f124a058aff8412959cefb5 schema:name Springer Nature - SN SciGraph project
139 rdf:type schema:Organization
140 N3f6e03fc6a4c4794a95f39a7b438cf9a rdf:first sg:person.01342335052.95
141 rdf:rest N9309913d91ad4ccbb2d06816a37e4878
142 N430936ba4fa64dd1966532cde29effea schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Humans
144 rdf:type schema:DefinedTerm
145 N48acac754e234b0299cb8745ffa33936 schema:issueNumber 4
146 rdf:type schema:PublicationIssue
147 N4f650c72bc01482aac98c81800f7d69f rdf:first sg:person.016654252332.36
148 rdf:rest N907e9816b58047708b4ac2626a4530e8
149 N56fb9ec579bc4ceaae6b9655e9af580e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Cadherins
151 rdf:type schema:DefinedTerm
152 N5875b1553d404c7482580299be260bbd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Neoplasm Invasiveness
154 rdf:type schema:DefinedTerm
155 N5ca4b867ef864746b7d2eb050921b4f7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Biomarkers, Tumor
157 rdf:type schema:DefinedTerm
158 N5d3bb014ffee4180825c7bdd6eec36e3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Male
160 rdf:type schema:DefinedTerm
161 N5dba2529a71141c78849b878c4c8bd67 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Gallbladder Neoplasms
163 rdf:type schema:DefinedTerm
164 N6c66bd1a3eb14ec9ae3a5c410b65eeb8 schema:name pubmed_id
165 schema:value 15554392
166 rdf:type schema:PropertyValue
167 N6d20e64f21f54c05a9675a37e6e4dfec rdf:first sg:person.014306602014.93
168 rdf:rest Ne4d474e9aac64fd19fde347a5ee6b477
169 N6f5407e283f149bfa27fe2d90efbb739 rdf:first sg:person.0733157352.71
170 rdf:rest N075cc5d1d2c645008c3e09ba9096efc9
171 N8f7b5503baa3453ca2ab7d89e63d3047 schema:name doi
172 schema:value 10.1023/b:clin.0000046177.70405.cb
173 rdf:type schema:PropertyValue
174 N907e9816b58047708b4ac2626a4530e8 rdf:first sg:person.01167712513.14
175 rdf:rest N3f6e03fc6a4c4794a95f39a7b438cf9a
176 N9309913d91ad4ccbb2d06816a37e4878 rdf:first sg:person.014234426664.03
177 rdf:rest N6f5407e283f149bfa27fe2d90efbb739
178 Naa6bffdbbbcb4026bee0ac29e8dabf85 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name Antibodies, Monoclonal
180 rdf:type schema:DefinedTerm
181 Nbebf6c78173340d99df54493a1c1679d schema:name dimensions_id
182 schema:value pub.1024529919
183 rdf:type schema:PropertyValue
184 Nddf2ce8a67934a7da578eba0010b3851 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
185 schema:name Mucin-1
186 rdf:type schema:DefinedTerm
187 Ne4d474e9aac64fd19fde347a5ee6b477 rdf:first sg:person.01356327470.60
188 rdf:rest rdf:nil
189 Nf40467e1394c4f39b7b3ce61ae70095b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
190 schema:name RNA, Messenger
191 rdf:type schema:DefinedTerm
192 Nff74ee61541d490eb17f1128ac1c88fd schema:volumeNumber 21
193 rdf:type schema:PublicationVolume
194 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
195 schema:name Medical and Health Sciences
196 rdf:type schema:DefinedTerm
197 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
198 schema:name Oncology and Carcinogenesis
199 rdf:type schema:DefinedTerm
200 sg:journal.1094856 schema:issn 0262-0898
201 1573-7276
202 schema:name Clinical & Experimental Metastasis
203 schema:publisher Springer Nature
204 rdf:type schema:Periodical
205 sg:person.011557753737.86 schema:affiliation grid-institutes:grid.20515.33
206 schema:familyName Todoroki
207 schema:givenName Takeshi
208 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011557753737.86
209 rdf:type schema:Person
210 sg:person.01167712513.14 schema:affiliation grid-institutes:grid.20515.33
211 schema:familyName Shoda
212 schema:givenName Junichi
213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01167712513.14
214 rdf:type schema:Person
215 sg:person.01342335052.95 schema:affiliation grid-institutes:grid.26999.3d
216 schema:familyName Miyahara
217 schema:givenName Naoki
218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01342335052.95
219 rdf:type schema:Person
220 sg:person.01356327470.60 schema:affiliation grid-institutes:grid.26999.3d
221 schema:familyName Irimura
222 schema:givenName Tatsuro
223 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01356327470.60
224 rdf:type schema:Person
225 sg:person.014234426664.03 schema:affiliation grid-institutes:grid.20515.33
226 schema:familyName Suzuki
227 schema:givenName Hideo
228 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014234426664.03
229 rdf:type schema:Person
230 sg:person.014306602014.93 schema:affiliation grid-institutes:grid.20515.33
231 schema:familyName Tanaka
232 schema:givenName Naomi
233 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014306602014.93
234 rdf:type schema:Person
235 sg:person.016654252332.36 schema:affiliation grid-institutes:grid.20515.33
236 schema:familyName Kawamoto
237 schema:givenName Toru
238 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016654252332.36
239 rdf:type schema:Person
240 sg:person.0733157352.71 schema:affiliation grid-institutes:None
241 schema:familyName Furukawa
242 schema:givenName Masato
243 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0733157352.71
244 rdf:type schema:Person
245 sg:pub.10.1007/bf01658724 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023802947
246 https://doi.org/10.1007/bf01658724
247 rdf:type schema:CreativeWork
248 sg:pub.10.1038/sj.bjc.6690355 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047938576
249 https://doi.org/10.1038/sj.bjc.6690355
250 rdf:type schema:CreativeWork
251 grid-institutes:None schema:alternateName 2nd Department of Surgery, Nagasaki Central National Hospital, Ohmura-shi, Nagasaki, Japan
252 schema:name 2nd Department of Surgery, Nagasaki Central National Hospital, Ohmura-shi, Nagasaki, Japan
253 rdf:type schema:Organization
254 grid-institutes:grid.20515.33 schema:alternateName Department of Gastroenterology, Institute of Clinical Medicine, The University of Tsukuba, Tsukubashi, Ibaraki, Japan
255 Department of Gastrointestinal Surgery, Institute of Clinical Medicine, The University of Tsukuba, Tsukubashi, Ibaraki, Japan
256 schema:name Department of Gastroenterology, Institute of Clinical Medicine, The University of Tsukuba, Tsukubashi, Ibaraki, Japan
257 Department of Gastrointestinal Surgery, Institute of Clinical Medicine, The University of Tsukuba, Tsukubashi, Ibaraki, Japan
258 rdf:type schema:Organization
259 grid-institutes:grid.26999.3d schema:alternateName Department of Cancer Biology and Molecular Immunology, Faculty of Pharmaceutical Sciences, The University of Tokyo, Bunkyoku, Tokyo, Japan
260 schema:name Department of Cancer Biology and Molecular Immunology, Faculty of Pharmaceutical Sciences, The University of Tokyo, Bunkyoku, Tokyo, Japan
261 Department of Gastroenterology, Institute of Clinical Medicine, The University of Tsukuba, Tsukubashi, Ibaraki, Japan
262 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...